Dr. Kiana Aran and Dr. Paul Grint appointed to CRISPR QC Board of Directors

Technology Driven Insights to Improve CRISPR Edit Outcomes

SAN DIEGO–(BUSINESS WIRE)–On June 09, 2022, CRISPR QC has announced that Paul Grint and Dr. Kiana Aran have been appointed to the board of directors.

“CRISPR QC’s technology is empowering scientists to put the puzzle pieces together of CRISPR editing in a way that was not before possible. Researchers and therapeutics companies can now better design CRISPR components to fit different applications. This insight is driving better understanding of CRISPR activity that will lead to an acceleration of game-changing gene therapies, developments in agriculture, and more,” says Dr. Kiana Aran.

Dr. Kiana Aran is a pioneer of combining CRISPR with modern electronics. In addition to inventing the CRISPR-Chip™, she is an Associate Professor of Medical Diagnostics and Therapeutics at Keck Graduate Institute, a member of the Claremont Colleges, and a visiting Assistant Professor at the University of California Berkeley. Dr. Aran also serves as a Consultant of Drug Delivery and Medical Diagnostics for the Bill & Melinda Gates Foundation. Her efforts have been recognized within the scientific community by the Clinical OMICs 10 under 40 Award, Athena Pinnacle Award in Life Sciences, and Nature Research Awards for Inspiring Women in Science: Scientific Achievement Category’s Overall Winner 2021. Dr. Aran is also the recipient of numerous grants to develop the next generation of electronic biosensors, including the NSF CAREER Award and multiple NIH RO1 and DARPA grants.

“CRISPR has the potential to finally cure genetic diseases where we are currently only able to treat the symptoms. With the insight CRISPR QC provides, therapeutics companies will be better able to develop efficacious treatments by truly understanding the activity of CRISPR and will allow regulators to ensure that these treatments are safe for the patients receiving them by being able to directly measure and report the mechanics at work,” says Paul Grint.

Grint has more than two decades of experience in biologics and small-molecule research and development, including serving on the Boards of Illumina, AmpliPhi Biosciences, and as the CEO of several companies that led to successful approval and commercialization of products in the infectious diseases, immunology, and oncology therapeutic areas. He is a Fellow of the Royal College of Pathologists, and a holds a medical degree from St. Bartholomew’s Hospital College, University of London. Dr. Grint’s ability to see the early potential in technology served Illumina well when Next Gen Sequencing was in its early days as it will CRISPR QC, with its platform for insight that is enabling the full potential of CRISPR-based cell and gene therapies.

The demand for CRISPR/Cas9 gene-editing has grown alongside the potential for therapeutic, animal production, and plant biology benefits. The need for quality control and insight has grown concurrently with advances and successes of CRISPR gene editing. At CRISPR QC, we help knowledge seekers obtain the data and information to develop better cell assay designs. At CRISPR QC we utilize our CRISPR-CHIP™ technology to provide CRISPR experts with the information to improve early activities and transition toward actionable results.


CRISPR QC is a biotechnology company dedicated to improving the knowledge of scientists and researchers to improve their CRISPR assay designs through technological innovation. Using market-leading solutions, we can identify CRISPR activity in amplicons and genomic DNA and model results of the CRISPR process In vivo vs. In vitro. Our service is available to therapeutic companies and academic researchers to help them accelerate the development of their CRISPR-based therapies and to animal production and plant biology scientists who seek to improve the food chain for humankind.

To learn more about CRISPR QC, visit www.crisprqc.com.


Ross Bundy, President